Abstract P1-10-14: Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive(HR+)/HER2-negative(-) metastatic breast cancer (mBC)
Daniele Generali(University of Trieste), Giuseppe Curigliano(University of Milan), Fabiola Giudici(University of Padua), Sabrina Nucera(University of Catania), Massimo Cristofanilli(Breast Cancer Care), Grazia Arpino(University of Naples Federico II), Paolo Vigneri(Humanitas University), Tomás Pascual(Breast Cancer Research Foundation), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Rodrigo Sánchez-Bayona(Hospital Universitario 12 De Octubre), Hope Rugo, Benedetta Conte(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Richard Tancredi(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Lucia Del Mastro(Ospedale Policlinico San Martino), Manuela Milani(Istituti Ospitalieri di Cremona), Carmen Criscitiello(University of Milan), Matteo Lambertini(Ospedale Policlinico San Martino), Francesco Schettini(Target (United States))
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k